½ÃÀ庸°í¼­
»óǰÄÚµå
1608127

¼¼°èÀÇ Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå : Á¦Ç°º°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Insulin Delivery Devices Market by Product (Insulin Injectors, Insulin Pens, Insulin Pumps), End-User (Homecare, Hospitals) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀº 2023³â¿¡ 285¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 306¾ï 1,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 8.00%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 489¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡´Â ´ç´¢º´ ȯÀÚ¿¡°Ô Àν¶¸°À» Åõ¿©Çϱâ À§ÇÑ ´Ù¾çÇÑ Á¦Ç°ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¿¡ ´ëÀÀÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ Çʿ伺Àº Àα¸ÀÇ ³ëÈ­, ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­, ºñ¸¸ ºñÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´ À¯º´·üÀÌ ¼¼°èÀûÀ¸·Î »ó½ÂÇϰí Àֱ⠶§¹®¿¡ Àν¶¸° Àü´Þ µð¹ÙÀ̽º´Â 1Çü ´ç´¢º´°ú 2Çü ´ç´¢º´ ¸ðµÎ °ü¸®¿¡ »ç¿ëµÇ¸ç ÃÖÁ¾ »ç¿ëÀÚ´Â °³ÀÎ, °Ç°­ °ü¸® °ø±ÞÀÚ, º´¿øÀÔ´Ï´Ù.ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´ °ü¸®¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í ȯÀÚÀÇ ÆíÀǼºÀ» ³ôÀÌ´Â Àåºñ ¼³°èÀÇ ±â¼úÀû Áøº¸, ÀçÅà °Ç°­ °ü¸® ¼Ö·ç¼Ç ½Å¿¡ ´ëÇÑ °ü½É Áõ°¡·Î »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â ½º¸¶Æ® Àν¶¸° Ææ°ú Àν¶¸° ÆßÇÁ¿Í Áö¼ÓÀûÀÎ Æ÷µµ´ç ¸ð´ÏÅ͸µÀ» ÅëÇÕ ÇÑ Æó¼â ·çÇÁ ½Ã½ºÅÛÀÇ Ã¤Åà Ȯ´ë¿¡ ÀÖ½À´Ï´Ù. »ó´çÈ÷ Çâ»óµÇ°í ½ÃÀå °ü°èÀÚ¿¡°Ô Å« ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Á¦ÇÑµÈ »óȯ Á¤Ã¥, ÷´Ü ÀåÄ¡ÀÇ ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á¿Í °°Àº °úÁ¦°¡ ½ÃÀå È®´ë¿¡ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ƯÈ÷ Àν¶¸° Åõ¿©¿¡ À־ ¿¹Ãø ºÐ¼®À» À§ÇÑ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕ¿¡ À־ ±â¼ú Çõ½ÅÀÇ Å« °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ °Ç°­ Ç÷§Æû°úÀÇ ¿¬°á¼ºÀ» È®´ëÇÔÀ¸·Î½á »õ·Î¿î ºñÁî´Ï½º ±æÀ» ¿­ ¼ö ÀÖ½À´Ï´Ù. ¼³¹®Á¶»ç´Â ÀåÄ¡ »ç¿ë¼º Çâ»ó ¹× Àν¶¸° Àü´Þ ½Ã½ºÅÛÀÇ Á¤È®¼º Çâ»ó¿¡ ÁßÁ¡À» µÑ ¼ö ÀÖ½À´Ï´Ù. ³ª³ë Àü´Þ ±â¼ú°ú »ý¹°ÇÐÀûÀ¸·Î ÅëÇÕµÈ ÀåÄ¡ÀÇ Áøº¸´Â ȯÀÚÀÇ Ãæ°Ý°ú °á°ú¸¦ ´õ¿í Å©°Ô º¯È­½Ãų ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÃâ±â¾÷Àº ¼ºÀåÀ» °è¼ÓÇϱâ À§ÇØ È¯ÀÚ Á᫐ ¼Ö·ç¼ÇÀ¸·Î Çõ½ÅÀ» ½ÇÇöÇØ¾ß ÇÏ¸ç °æÀïÀÌ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. Áö¿ª °Ç°­ °ü¸® Á¤Ã¥, ȯÀÚÀÇ Àα¸ Åë°è¸¦ ºÐ¼®ÇÏ°í ´ë±Ô¸ð ½ÃÇèÀ» À§ÇØ ÀÇ·á ½Ã¼³°ú Çù·ÂÇÔÀ¸·Î½á ½ÃÀå Á¡À¯À²À» ¾ò°í È®´ëÇϱâÀ§ÇÑ ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖÀ¸¸ç Á¾ÇÕÀûÀÔ´Ï´Ù. ÀÌÇØ¸¦ º¸ÀåÇϰí ȯÀÚÀÇ ¿ä±¸¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 285¾ï 5,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 306¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 489¾ï 3,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 8.00%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯È­¸¦ °Þ°í ÀÖ½À´Ï´Ù. È­¿Í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÏ´Â °Í ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º Áúȯ Áõ°¡¿Í Àν¶¸° Àü´ÞÀ» À§ÇÑ Ã·´Ü ÀåÄ¡ÀÇ Ã¤¿ë
    • ¼¼°è¿¡¼­ Áõ°¡ÇÏ´Â ´ç´¢º´ Àα¸¿Í ºñ¸¸ Àα¸
    • ÃֽŠÀν¶¸° Àü´Þ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÇ½Ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ °íºñ¿ë°ú º¸Çè Àû¿ë ºÎÁ·
  • ½ÃÀå ±âȸ
    • Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ ±â¼úÀû Áøº¸
    • ÀÚµ¿È­µÈ Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ ¼Ò°³
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¤°ú º¹ÀâÇÑ Á¦Ç° ½ÂÀÎ ÇÁ·Î¼¼½º

Porter's Five Forces : Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.¤·

Àü·« ºÐ¼® ¹× ±ÇÀå Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º Áúȯ Áõ°¡¿Í Àν¶¸° Åõ¿©¸¦ À§ÇÑ Ã·´Ü ±â±âÀÇ µµÀÔ
      • Àü ¼¼°è¿¡¼­ ´ç´¢º´°ú ºñ¸¸ Àα¸°¡ Áõ°¡
      • ÃֽŠÀν¶¸° Àü´Þ µð¹ÙÀ̽º¿¡ °üÇÑ ¼ÒºñÀÚÀÇ ÀÇ½Ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ ºñ¿ëÀÌ ³ô°í º¸Çè Àû¿ë ¹üÀ§°¡ Á¼´Ù
    • ±âȸ
      • Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ ±â¼úÀû Áøº¸
      • ÀÚµ¿È­µÈ Àν¶¸° Àü´Þ µð¹ÙÀ̽ºÀÇ ¼Ò°³
    • °úÁ¦
      • Á¤ºÎ ±ÔÁ¦ÀÇ ¾ö°ÝÈ­¿Í Á¦Ç° ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ º¹ÀâÈ­
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå : Á¦Ç°º°

  • Àν¶¸° ÁÖ»ç±â
  • Àν¶¸° Ææ
  • Àν¶¸° ÆßÇÁ
  • Àν¶¸° ÁÖ»ç±â

Á¦7Àå Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àν¶¸° Àü´Þ µð¹ÙÀ̽º ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Baxter International Inc
  • Becton, Dickinson and Company
  • Biocon Ltd.
  • Braun Melsungen AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Ltd.
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche, Ltd.
  • Insulet Corporation
  • Johnson & Johnson
  • Medtronic PLC
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi SA
  • Tandem Diabetes Care, Inc.
  • TOPAS Advanced Polymers GmbH
  • Ypsomed AG
  • Zealand Pharma A/S
BJH 24.12.19

The Insulin Delivery Devices Market was valued at USD 28.55 billion in 2023, expected to reach USD 30.61 billion in 2024, and is projected to grow at a CAGR of 8.00%, to USD 48.93 billion by 2030.

The insulin delivery devices market encompasses a wide range of products designed to administer insulin to individuals with diabetes. These devices include syringes, insulin pens, insulin pumps, and jet injectors, each catering to different patient needs and preferences. The necessity for such devices stems from the global rise in diabetes prevalence, compounded by aging populations, lifestyle changes, and increasing obesity rates. Insulin delivery devices are employed in both Type 1 and Type 2 diabetes management, with end-users comprising individuals, healthcare providers, and hospitals. Growth in this market is driven by heightened awareness of diabetes management, technological advancements in device design enhancing patient convenience, and a stronger focus on home healthcare solutions. Emerging opportunities lie in the increasing adoption of smart insulin pens and closed-loop systems that integrate continuous glucose monitoring with insulin pumps. These innovations can significantly enhance glycemic control, presenting substantial opportunities for market players. However, challenges such as high costs, limited reimbursement policies, and safety concerns of advanced devices hamper market expansion. Additionally, regulatory hurdles for new device approvals pose barriers. Despite these challenges, the market offers significant potential for innovation, particularly in the integration of artificial intelligence and machine learning for predictive analytics in insulin administration. Expanding device connectivity with digital health platforms can also offer new business avenues. Research can focus on enhancing the user-friendliness of devices and improving the precision of insulin delivery systems. Advancements in nano-delivery technologies and biologically integrated devices may further revolutionize patient adherence and outcomes. The market remains competitive, with participants needing to align innovations with patient-centric solutions to continue fostering growth. Analyzing regional healthcare policies, patient demographics, and collaborating with healthcare facilities for large-scale trials can provide actionable insights into capturing and expanding market shares, ensuring a comprehensive understanding and addressing patient needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 28.55 billion
Estimated Year [2024] USD 30.61 billion
Forecast Year [2030] USD 48.93 billion
CAGR (%) 8.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insulin Delivery Devices Market

The Insulin Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing chronic diseases and adoption of advanced devices for insulin delivery
    • Increasing diabetic & obese population across the globe
    • Rising consumer awareness about the latest insulin delivery devices
  • Market Restraints
    • High cost of insulin delivery devices and lack of insurance coverage
  • Market Opportunities
    • Technological advancements in insulin delivery devices
    • Introduction of automated insulin delivery devices
  • Market Challenges
    • Increasing stringent government rules and complicated product approval process

Porter's Five Forces: A Strategic Tool for Navigating the Insulin Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insulin Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insulin Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insulin Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insulin Delivery Devices Market

A detailed market share analysis in the Insulin Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insulin Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insulin Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Insulin Delivery Devices Market

A strategic analysis of the Insulin Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Insulin Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc, Becton, Dickinson and Company, Biocon Ltd., Braun Melsungen AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Insulet Corporation, Johnson & Johnson, Medtronic PLC, Merck & Co., Inc., Novo Nordisk A/S, Sanofi SA, Tandem Diabetes Care, Inc., TOPAS Advanced Polymers GmbH, Ypsomed AG, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Insulin Injectors, Insulin Pens, Insulin Pumps, and Insulin Syringes.
  • Based on End-User, market is studied across Homecare and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing chronic diseases and adoption of advanced devices for insulin delivery
      • 5.1.1.2. Increasing diabetic & obese population across the globe
      • 5.1.1.3. Rising consumer awareness about the latest insulin delivery devices
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of insulin delivery devices and lack of insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in insulin delivery devices
      • 5.1.3.2. Introduction of automated insulin delivery devices
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing stringent government rules and complicated product approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Insulin Delivery Devices Market, by Product

  • 6.1. Introduction
  • 6.2. Insulin Injectors
  • 6.3. Insulin Pens
  • 6.4. Insulin Pumps
  • 6.5. Insulin Syringes

7. Insulin Delivery Devices Market, by End-User

  • 7.1. Introduction
  • 7.2. Homecare
  • 7.3. Hospitals

8. Americas Insulin Delivery Devices Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Insulin Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Insulin Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Baxter International Inc
  • 3. Becton, Dickinson and Company
  • 4. Biocon Ltd.
  • 5. Braun Melsungen AG
  • 6. Bristol-Myers Squibb Company
  • 7. Daiichi Sankyo Company, Ltd.
  • 8. Dr Reddy's Laboratories Ltd
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche, Ltd.
  • 11. Insulet Corporation
  • 12. Johnson & Johnson
  • 13. Medtronic PLC
  • 14. Merck & Co., Inc.
  • 15. Novo Nordisk A/S
  • 16. Sanofi SA
  • 17. Tandem Diabetes Care, Inc.
  • 18. TOPAS Advanced Polymers GmbH
  • 19. Ypsomed AG
  • 20. Zealand Pharma A/S
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦